The expression of CD 15 antigen on myeloid leukaemia cells--a new prognostic index for complete remission and for survival.
377 untreated acute leukaemia patients were categorized according to FAB and cytochemical criterials and simultaneously phenotyped with the use of 6-21 monoclonal antibodies (MoAb) of VI series (W. Knapp, Vienna). The leukaemia phenotype was compared with the patients outcome after treatment. In adult ANLL patients a positive relationships was proved statistically between the expression of the CD 15 cell differentiation antigen on leukaemic blasts and the CR rate (p less than 0.01, chi 2 test). Also a comparison of the Kaplan-Meier survival curves revealed that the CD 15 positive group of ANLL patients has a better outcome than the CD 15 negative one (p less than 0.01, by Wilcoxon and Log-rank tests). Thus, examination of cell differentiation antigens could be a useful addition to existing risk assignment in acute leukaemia.
Hołowiecki
J
J
International Society of Chemo-Immuntherapy Cooperative Group Vienna, Austria.
Lutz
D
D
Krzemień
S
S
Schranz
V
V
Jagoda
K
K
Hołowiecka
B
B
Graf
F
F
Kelenyi
G
G
Callea
V
V
Brugiatelli
M
M
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000401:mortality; D016256:Lewis X Antigen; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D014408:Biomarkers, Tumor; D016256:Lewis X Antigen